mission

To inspire hope by restoring lost capability and unlocking the full potential of human intelligence

The high-performance BCI platform company combining frontier neural engineering with clinical discipline to move brain-computer interfaces from
restoring human function to advancing human possibility. Our technology is designed to help people participate more fully in life by restoring capabilities
lost to disease or injury, while expanding the potential to work, contribute, create, and pursue what gives life meaning.

history

Signals over time

Clinical Milestone

2026

First human implantation of the Connexus® BCI in the FDA-approved Connect-One Clinical Study.

Scientific Milestone

2025

Completed the first in-human recording.

Key Hire

2025

Neurosurgeon Stephen Ryu, M.D. joins Paradromics as CMO.

Partnerships

2025

Clinical study investigators announced: David Brandman, M.D., Ph.D. and Daniel Rubin, M.D., Ph.D.

Scientific Milestone

2024

Pre-clinical work starts for Early Feasibility Study FDA submission.

Key Hire

2023

BCI veteran Vikash Gilja joins as CSO.

Corporate Expansion

2023

Machine Learning and Data Science office opens in Oakland, CA.

Scientific Milestone

2020-2022

First pre-clinical chronic recordings from Connexus® BCI.

Key Hire

2019

Medical device veteran James Burrows joins as COO.

Headquarters

2019

Established in Austin, TX.

FDA Milestones

fda milestone 01

March 2023

Breakthrough Device Designation #1

Speech decoding

fda milestone 02

APRIL 2024

Breakthrough Device Designation #2

Digital device control

fda milestone 03

APRIL 2024

Total Product Life Cycle Advisory Program (TAP)

Acceptance

fda milestone 04

NOVEMBER 2025

Investigational Device Exemption (IDE)

Approval to initiate clinical study

leadership

Frontier innovation. Medical-device discipline.

Paradromics is built to innovate like a frontier deep-tech company and execute like a mature Class III medical-device company. Our leadership brings together the scientific founders and neural-interface experts behind our platform with experienced operators who have advanced implantable medical devices through clinical development, FDA approval, commercialization, and scale.

Matt Angle, PhD

Founder and CEO

Yifan Kong, PhD

Chief of Staff to the CEO

James Burrows

Chief Operating Officer

Vikash Gilja, PhD

Chief Scientific Officer

Justin Smith

Chief Strategy Officer

Stephen Ryu, MD

Chief Medical Officer

Kurtis Nishimura,PhD

Chief Technology Officer

William Marks, MD

Chief Clinical Officer

Matt Marino

Executive VP of Finance

Lydia Hancock

VP of Quality and Regulatory Affairs

Sofi Hoysal

vp of people

Rich Phillips

VP of Marketing & Communications

Shaoyu Qiao, PhD

VP of Neuroscience

Scott Way

General Counsel

Board of Directors

Matt Angle, PhD: Founder and CEO, Paradromics
Amy Kruse, PhD: Chief Investment Officer
Helmy Eltoukhy, PhD: Partner, Green Sands Equity and Co-Founder, Chairman and Co-CEO, Guardant Health
Michael Rousseau: Former CEO of St. Jude Medical
Zia Huque: General Partner, Prime Movers Lab

View Open Roles

collaborations

We are proud to work with world-renowned institutions that lead the world in clinical and application research.

Learn More

University of California, Davis

University of Michigan Health

University of Pittsburgh

Stanford
University

Massachusetts General Hospital

News & Insights

Stories and developments shaping the BCI industry

Breaking News

Paradromics Achieves Real-Time Speech with Connexus® Brain-Computer Interface

Read Article